Frontiers
Browse
Data_Sheet_1_Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor.docx (472.63 kB)

Data_Sheet_1_Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor.docx

Download (472.63 kB)
dataset
posted on 2019-06-21, 12:53 authored by Mingpeng Fu, Qi He, Zilong Guo, Xiaoran Zhou, Heli Li, Liang Zhao, Hongling Tang, Xiaoqi Zhou, Huifen Zhu, Guanxin Shen, Yong He, Ping Lei

Bispecific T-cell engager antibodies (BiTE) have been explored as a means to recruit cytolytic T cells to kill tumor cells. The transferrin receptor (TfR) is highly expressed on the surface of rapidly proliferating tumor cells. Therefore, it holds great potential in T cell redirecting therapies. In this research, we developed a BiTE targeting TfR and CD3 (TfR-BiTE) and studied its therapeutic impact on TfR-positive cancer. TfR-BiTE had the ability to induce the selective lysis of various TfR-positive cancer cells through the activation of T cells, the release of cytokines, and then the coming proliferation of T cells, whereas TfR-negative cells were not affected. In a subcutaneous HepG2 xenograft model, low concentrations of TfR-BiTE inhibited tumor growth. Overall, these results reveal that TfR-BiTE can selectively deplete TfR-positive HepG2 cells; hence, it represents a novel immunotherapeutic approach for the treatment of hepatocellular carcinoma.

History